Study: Black patients underrepresented in pivotal CAR T-cell trials

The number of Black participants who received chimeric antigen receptor (CAR) T-cell therapies for hematologic cancers in pivotal clinical trials ranged from about 2% to 5%, suggesting the need for policy changes to increase trial enrollment of minority patients, according to an analysis published in JAMA Network Open.